Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Take Ltd (TAKE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532890 NSE: TAKE IT - Software | Small Cap | Take Share Price
₹16.20 -0.28 (-1.70%)
As on 22-Sep'26 13:13
Take Ltd (TAKE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532890 NSE: TAKE IT - Software | Small Cap | Take Share Price
₹16.20 -0.28 (-1.70%)
As on 22-Sep'26 13:13
Key Metrics
Valuation Multiples
Market Cap
₹244 Cr.
Current Price
₹16.2
52-Week Low / High
₹10 / 50
TTM EPS
₹0.9
TTM Sales
₹84.6 Cr.
Book Value per Share
₹2.2
P/E Ratio
19.01
Higher than its 5-year historical median
Industry PE
20.7
Price to Book (P/B)
7.60
Higher than its 5-year historical median
Price to Sales (P/S)
2.88
Lower than its 5-year historical median
EV/EBITDA
39.01
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
12.67%
Outperforms industry median
Return on Capital Employed (ROCE)
13.63%
Outperforms industry median
Return on Assets (ROA)
1.21%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-83.39%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹11 Cr.
Equity
₹14.8 Cr.
Face Value
₹1
All Time Low / High
₹4.70 / 308.30
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Weak
Is Take Ltd a good quality company?
Take Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Take Ltd performance compare with that of its Peers?
Revenue growth of Take Ltd vs industry peers?
Take Ltd revenue CAGR is -100.00%, compared to the industry median CAGR of 0%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Take Ltd?
Promoters hold 0.00% of the Take Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Take Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -20.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Take Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.8% | 3.9% | 2.5% | 2.6% | 1% | -0.9% | -0.5% | 1.8% | -35.3% | 18% | - |
| Value Creation Index ⓘ | -0.6 | -0.7 | -0.8 | -0.8 | -0.9 | -1.1 | -1.0 | -0.9 | -3.5 | 0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 23.6 | 18.8 | 2.4 | 22 | 2.5 | 12 | 18 | 56.2 | 5.4 | 0.9 | 12 |
| Sales YoY Gr. | - | -20.1% | -87.1% | 800% | -88.8% | 387% | 49.6% | 212.4% | -90.4% | -83.4% | - |
| Adj EPS ⓘ | 0.7 | 0.2 | 0.3 | 0.5 | 0.2 | -0.2 | -0.5 | 0.5 | -2.8 | 0.7 | 0.4 |
| YoY Gr. | - | -67.1% | 43.5% | 36.4% | -62.2% | -235.3% | NA | NA | -611.1% | NA | - |
| BVPS (₹) ⓘ | 26.5 | 38.3 | 51.5 | 50.9 | 51 | 51.7 | 19.5 | 20.4 | 6.5 | 1.7 | 2 |
| Adj Net Profit ⓘ | 8.4 | 3 | 4.8 | 6.7 | 2.5 | -3.4 | -7.7 | 8 | -40.8 | 10.2 | 6 |
| Cash Flow from Ops. ⓘ | -10.8 | -33 | -24 | 12.9 | -14.9 | -2.7 | 32.6 | 26.9 | -4.5 | -19.5 | - |
| Debt/CF from Ops. ⓘ | -6.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -30.4% | -18.3% | -63.2% | -83.4% | ||||
| Adj EPS ⓘ | -0.2% | 32.3% | NA | NA | ||||
| BVPSⓘ | -26.1% | -49.1% | -55.3% | -73% | ||||
| Share Price | -20.6% | -20.2% | -10.7% | 54.7% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.6 | 0.7 | 0.8 | 0.9 | 0.3 | -0.4 | -1.4 | 2.7 | -20.5 | 16.8 | 20.9 |
| Op. Profit Mgn % ⓘ | 22.1 | -16.7 | -664.4 | -63.2 | -685.8 | -25.8 | -74.2 | 5.1 | -394.7 | -222.7 | -3 |
| Net Profit Mgn % ⓘ | 35.6 | 16.2 | 197.2 | 30.3 | 101.7 | -28.2 | -42.6 | 14.2 | -752.7 | 1130.9 | 48.2 |
| Debt to Equity ⓘ | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 789 | 1,936 | 26,120 | 3,642 | 35,731 | 7,599 | 3,694 | 585 | 2,813 | 9,144 | 0 |
| Cash Conv. Cycle ⓘ | -130 | -17 | 272 | 34 | 979 | 75 | -79 | -314 | -261 | -89 | 0 |
Valuation of Take - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 653 | 189 | 4 | 0 |
| Operating Expenses > ⓘ + | 866 | 1,082 | 1,281 | 1,656 | 2,044 | 847 | 643 | 208 | 25 | 7 |
| Operating Profit > ⓘ | 164 | 262 | 306 | 383 | 169 | -73 | 10 | -19 | -21 | -7 |
| Operating Profit Margin (%) | 15.9% | 19.5% | 19.3% | 18.8% | 7.6% | -9.4% | 1.5% | -10.1% | -586.0% | - |
| Other Income > ⓘ + | 21 | 13 | 6 | 11 | 26 | 12 | 17 | 8 | 1 | 10 |
| Interest > ⓘ | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 | 2 | 2 |
| Depreciation > ⓘ | 25 | 87 | 104 | 154 | 167 | 115 | 76 | 17 | 1 | 0 |
| Profit Before Tax > ⓘ | 145 | 165 | 188 | 216 | -13 | -439 | -78 | -45 | -62 | 1 |
| Tax > ⓘ | 20 | 19 | 28 | 37 | -2 | 14 | 5 | 2 | 4 | 0 |
| Profit After Tax | 125 | 146 | 160 | 178 | -11 | -452 | -83 | -47 | -66 | 1 |
| PAT Margin (%) | 12.1% | 10.9% | 10.1% | 8.8% | -0.5% | -58.4% | -12.7% | -24.8% | -1,842.8% | - |
| Adjusted EPS (₹) | 10.0 | 10.9 | 11.0 | 12.1 | -0.9 | -30.9 | -53.5 | -6.9 | -8.2 | 2.6 |
| Dividend Payout Ratio (%) | 10% | 9.20% | 14.60% | 8.20% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 631 | 903 | 1,321 | 1,509 | 1,564 | 1,114 | 171 | 107 | -9 | 21 | |
| Debt + | 318 | 221 | 308 | 455 | 514 | 450 | 45 | 27 | 23 | 0 | |
| Minority Interest | 40 | 42 | 8 | 9 | 10 | -0 | -0 | 0 | 0 | 0 | |
| Trade Payables | 50 | 46 | 49 | 14 | 61 | 42 | 29 | 24 | 17 | 1 | |
| Others Liabilities ⓘ | 174 | 157 | 154 | 344 | 315 | 221 | 976 | 64 | 55 | 14 | |
| Total Liabilities ⓘ | 1,214 | 1,369 | 1,840 | 2,331 | 2,464 | 1,826 | 1,221 | 222 | 86 | 36 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 73 | 83 | 0 | |
| CWIP ⓘ | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 11 | 0 | 0 | |
| Investments ⓘ | 21 | 10 | 59 | 10 | 17 | 7 | 0 | 0 | 0 | 0 | |
| Inventories | 22 | 17 | 17 | 18 | 3 | 1 | 1 | 1 | 1 | 0 | |
| Trade Receivables | 301 | 436 | 469 | 525 | 701 | 434 | 82 | 30 | 7 | 0 | |
| Cash Equivalents | 128 | 110 | 341 | 70 | 45 | 39 | 29 | 11 | 1 | 3 | |
| Others Assets ⓘ | 196 | 221 | 323 | 576 | 463 | 411 | 1,004 | 96 | -5 | 33 | |
| Total Assets ⓘ | 1,214 | 1,369 | 1,840 | 2,331 | 2,464 | 1,826 | 1,221 | 222 | 86 | 36 | |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 148 | 56 | 121 | 104 | 211 | 135 | 120 | 20 | 9 | -16 |
| Cash Flow From Investing Activity ⓘ + | -257 | -129 | -179 | -485 | -236 | -57 | -31 | -2 | -7 | 22 |
| Cash Flow From Financing Activity ⓘ + | 114 | 56 | 301 | 100 | 21 | -84 | -55 | -36 | -12 | -3 |
| Net Cash Flow ⓘ | 5 | -17 | 244 | -281 | -4 | -6 | 35 | -18 | -10 | 3 |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 21.61 | 19.05 | 14.37 | 12.61 | -0.71 | -33.78 | -12.9 | -33.82 | N/A | 12.67 |
| ROCE (%) | 18.78 | 17.74 | 14.91 | 13.21 | 1.38 | -21.31 | -5.19 | -19.83 | N/A | 13.63 |
| Asset Turnover Ratio | 0.96 | 1.04 | 0.99 | 0.98 | 0.92 | 0.36 | 0.43 | 0.26 | 0.02 | 0 |
| PAT to CFO Conversion(x) | 1.18 | 0.38 | 0.76 | 0.58 | N/A | N/A | N/A | N/A | N/A | -16 |
| Working Capital Days | ||||||||||
| Receivable Days | 96 | 100.10 | 104.10 | 89 | 101.10 | 267.50 | 144.10 | 107.70 | 1,879 | 0 |
| Inventory Days | 7.90 | 5.30 | 3.90 | 3.10 | 1.70 | 1 | 0.40 | 1.40 | 79.70 | 0 |
| Payable Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Take Ltd FAQs
The current trading price of Take on 22-Sep-2026 13:13 is ₹16.20.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Take stood at ₹243.8 Cr
The latest P/E ratio of Take as of 21-Sep-2026 is 41.73.
The latest P/B ratio of Take as of 21-Sep-2026 is 8.28.
The 52-week high of Take is ₹49.90 and the 52-week low is ₹10.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Take is ₹11.97 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Take Ltd is a average quality company.
The key valuation ratios of Take Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Take Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Take Ltd
TAKE Solutions is a globally-recognized domain-leader in Life Sciences and Supply Chain Management. TAKE leverages its domain expertise, innovation-driven technology, best practices and people strength to offer clients transformative full services across clinical development, and point services in supply chain. In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums.
With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Its global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers. In Supply Chain Management, TAKE focuses on high-margin niches in engineering services, and supply chain collaboration. Its IP-led approach enables its clients to automate supply chain processes, track, trace & control at item level, mandate supplier compliance, and streamline material & shipment movement, and thus optimize their processes. With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange.
Business area of the company
The company delivers domain-intensive services in Life Sciences and Supply Chain Management. The company offers clients a unique combination of full service Clinical, Regulatory and Safety services with unique technology expertise. The Company's services span clinical trials to regulatory submissions to post-marketing strategy with insights derived through proprietary industry network forums.
Products and services
Life Sciences:
- Life sciences home: implementation of clinical data standards for sponsor process enhancement and preparation of compliant clinical data. Services focused on leveraging the standardization process into Clinical Study and Summary (ISS/ISE) reports.
- Clinical data offerings: SDTM consultation and Full clinical data lifecycle services, from CRF design to ISS/ISE.
- Regulatory offerings: PharmaReady, an exclusive brand of TAKE Solutions, is a fully integrated web-based eDMS and eCTD Submissions Solution Suite.
- Drug safety offerings: Complete Pharmacovigilance Safety System and Clinical Trials Safety Surveillance.
Supply Chain Management:
- Demand Driven Supply Network
- Demand Driven Distribution & Fulfillment
- Mobile Applications & Auto-ID
- Global Trade Management
Company’s technology products and solutions are:
- Business Process Management Solutions- TAKE RTE (real time enterprise)
- TAKE BI Solutions, the Business Intelligence practice of TAKE Solutions, delivers custom solutions that enable companies to tap the full potential of their business capabilities by helping them access, analyze and share information anytime and anywhere.
- Microsoft solutions
- Enterprise desktop management solutions
Awards
- 2008: Recognized by Deloitte as India’s 10th fastest growing technology company
- 2009: Listed in Food Logistics magazine’s FL 100+ Software & Technology Providers list for third consecutive year
- 2010: Received MMA (Madras Management Association) award for Managerial Excellence 2010 in the Services category
- 2010: Recognized by Supply Chain Brain as a Great Supply Chain Partner 2010 for fourth consecutive year
- 2012: Recognized for “Significant Contribution to SCM field” at Spectrum Confluence 2012 organized by Indian Institute of Materials Management (IIMM) Chennai
- 2012: Listed on the 2012 Supply and Demand Chain Executive 100 List for the second consecutive year
- 2012: Recognized as TOP 100 Logistics IT Providers by Inbound Logistics magazine
- 2013: Emerged as Asia’s Second Best Employer Brand. Declared as Best among 30 Companies from across 33 countries in Singapore
- 2013: Recognized by Supply Chain Brain’s “2012 Great Supply Chain Partner” list
- 2013: Named in Software Magazine’s 30th Annual Software 500 as one of the world’s largest software and service companies
- 2013: Ranked by Inc. India magazine as one of India’s fastest growing top 500 mid-size companies
- 2014: Won the Best Employer Brand Award at the World HRD Congress, with a total of 14 award wins
- 2014: Named in 2013 Supply and Demand Chain Executive 100
- 2014: Listed in Software Magazine’s 31st ‘Annual Software 500’ ranking for the second consecutive year
- 2015: Ranked 2nd as the Dream Employer of Year, in Technology, at the World HRD Congress, with a total of 16 award wins
- 2015: Named in Software Magazine’s 32nd Annual Software 500 ranking of the world’s largest software and service providers for the third consecutive year
- 2016: Received a Special Commendation for Excellence in Corporate Governance at the Golden Peacock Awards
- 2016: Declared ‘HR Company of the Year’ from amongst over 400 companies at the World HRD Congress
- 2016: Adjudged the ‘Most Admired Brand – IT’ at the 5th Asian Customer Engagement Forum Awards that recognize excellence in Branding, Marketing and CSR
- 2017: Received the Golden Peacock Award for Excellence in Corporate Governance
- 2017: Chosen as one of the ‘Great Places to Work’ for its exemplary workplace culture
- 2017: Awarded Silver recognition level by EcoVadis for Sustainability & CSR Performance
- 2017: Received awards for the ‘Most Effective Campaign’, “Best use of video content’ and ‘Best Media Relations/PR at the prestigious Asian Customer Engagement Forum Awards
- 2017: Received titles of ‘Dream Company to Work For’ and ‘Best Employer Brand’, and 27 other titles at the World HRD Congress
- 2018: Won the award for Best Employer Brand for the 2nd consecutive year at the World HRD Congress 2018, and ranked 3rd in the Times Ascent presents Dream Companies to Work For category
- 2018: Earned a place in the Great Place to Work global listing, the global authority on building, sustaining & recognizing exemplary workplace culture and best practices
- 2018: Bestowed with the Golden Peacock Award for Excellence in Corporate Governance, for the 2nd consecutive year in 2018
- 2019: Awarded Silver recognition level by EcoVadis for Sustainability & CSR Performance
- 2020: CEO Insights Top 10 Clinical Trials Service Providers - 2020
Milestones
2000-2004
- Inaugurated North American headquarters at Princeton, New Jersey, USA
- TAKE Solutions was founded in Chennai, India
2007-2010
- Inaugurated a state-of-the-art global delivery center in Chennai, India
- Acquired OnSphere Corporation, Raleigh, North Carolina, USA, an IP-driven leader in regulatory compliance for Life Sciences
- Launched OneSCM, a multi-tenant SaaS platform to improve enterprise supplier management
- Acquired ClearOrbit, a Supply Chain Management software company in Austin, Texas, USA
- Registered a successful IPO and listed on the Bombay Stock Exchange and the National Stock Exchange in India.
2011-2014
- Recognized as a leader in IDC MarketScape on Drug Safety Services Worldwide Life Science Drug Safety Services 2013 Vendor Assessment
- Acquired UK-based WCI Consulting Group, a leading patient safety and compliance advisor to the Life Sciences industry
- Launched SafetyReady to increase the efficiency of Oracle Argus Safety Suite for Life Sciences
- Recognized as a Leader in IDC MarketScape: Worldwide Life Sciences R&D IT Outsourcing 2011
2015
- Launched cdsnet, a proprietary industry network on Clinical Data Strategy
- Launched Latin American Regulatory Operations Hub in Bogota, Columbia
- Awarded patent by the United States Patent and Trademark Office (USPTO) for “Method for Optimizing Clinical Data Standardization”
- Launched India’s first propriety industry network on pharmacovigilance, pvindia
- Launched pharmaReady 6.0, an update to proprietary web-based electronic document management and eSubmission solution for Life Sciences
2016
- Acquired Ecron Acunova, a full-service CRO with Clinical & BA/BE capabilities
- 100th pharmaReady customer win
2017
- Navitas Life Sciences named as a Leader in IDC MarketScape: Worldwide Life Science Drug Safety Services 2017 Vendor Assessment
- Consolidated Life Sciences businesses under the brand Navitas Life Sciences to provide full services across Clinical, Regulatory and Safety
- Launched Labeling Assessment Express to improve End-to-End labeling for Life Sciences
- Celebrated the landmark 15th year of its proprietary Life Sciences industry network forums
- Updated and significantly expanded OneSCM Supply Chain Collaboration Suite
- Launched the Gemini Series Android App for Smartphones
2018
- Inaugurated satellite hub in Chennai to deliver end-to-end dossier submission for APAC region for one of the largest global pharma companies
- Navitas Life Sciences recognized as ‘Leader’ in the IDC MarketScape: Drug Safety Services 2018 Vendor Assessment as one of only 8 vendors selected based on stringent research and due diligence
- Expanded operations in Colombia to offer full-service clinical, regulatory and pharmacovigilance/safety and technology offerings across Latin America
- Gartner recognized the Company amongst Top 20 Global Solution Providers in its Market Guide for Track-and-Trace and Serialization Software Providers for Life Sciences Companies
- TAKE recognised in CIO Review’s ‘20 Most Promising Pharma and Life Sciences Tech Companies'
- Inaugurated state-of-the-art Clinical facility in Chennai to conduct Bioavailability & Bioequivalence studies
2019-20
- Everest Group's Life Sciences Clinical Trials Products PEAK Matrix Assessment 2019 recognized Navitas Life Sciences as a Major Contender
- Acquired US-based, full-service contract research organization (CRO) and health-research company KAI Research
- Acquired DataCeutics, an American Clinical Data Sciences services company that provides quality SAS based statistical programming, clinical reporting and clinical data management
- 175+ customers for pharmaREADY, its cloud-based Regulatory Submissions management platform
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
